The use of AMGOFIL:
Reduces the incidence of infection related morbidity & mortality in patients with febrile neutropenia.
• Statically significant reduction from 77% in placebo group to 40% in Filgrastim group. [10]
• Filgrastim used for ≥ 7 days had a lower incidence of febrile neutropenia compared with dosing of < 7 days. [11]
Allows cancer patients to get an earlier & more rapid neutrophil recovery and continue safely on DOSE INTENSE THERAPY.
• A transient increase in neutrophil count is seen in 1-2 days after initiation of Filgrastim therapy. To ensure a sustained therapeutic response, it should be administered daily for 2 weeks or until ANC reaches normal limit. [10]
• If patients continue chemotherapy without Filgrastim, there is 50% decrease in neutrophil count within 1-2 days, with a return to pretreatment level within 7 days.
Ref: [10] Crawford J, et al, N Engl J Med. 1991;325: 164-170.
[11] Scott SD, et al, J Manag Care Pharm. 2003;9(suppl 2): 15-21.
Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.
Read moreColorectal cancer is a major cause of morbidity and mortality, being one of the most common malignant tumors in the world.
Read moreCancer of the prostate is the most common malignancy in elderly men
Read moreChemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.
Read moreSome types of cancer may cause bone damage leading to high levels of blood calcium and lesions that cause severe bone pain, bone masses & fractures.
Read more